GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation

COPENHAGEN, DENMARK, February 4, 2026 / EINPresswire.com / -- SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with nextgeneration multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s

Saving the Lives of Our Tiniest Population Born with Congenital Heart Disorders, the Institute is Among Few in the Nation Performing These Complex Interventions MIAMI, Feb. 4, 2026 /PRNewswire/ -- From partial heart transplantation and complex biventricular repairs to innovative procedures in the catheterization laboratory, Nicklaus Children's Heart Institute is pioneering new options for children with pediatric heart conditions. These cardiovascular procedures offer hope and solutions to the hu

AUDUBON, Pa., Feb. 4, 2026 /PRNewswire/ -- AIROS® Medical, Inc., a medical technology manufacturer specializing in compression therapy systems that treat peripheral vascular disorders, today announced the launch of the U.S. Food and Drug Administration (FDA) 510(k)-cleared ARTAIRA® Arterial Compression Device. ARTAIRA is a non-invasive intermittent pneumatic compression device that increases blood flow and circulation to the lower extremities to treat patients with some symptoms of peripheral ar

题目：AI-Driven Polypharmacology in Small-Molecule Drug Discovery 这篇综述论文的核心创新，并不体现在提出某一个全新的算法或单一模型，而在于系统性地整合并重构了“多靶点药物设计（Polypharmacology）在 AI 时代的完整技术图景”，为小分子药物研发提供了一条清晰、可操作的范式升级路径。 首先，论文从药物研发范式层面，明确提出“理性多靶点设计”已从偶然现象转变为可被系统规划的设计目标。文章强调，多靶点并非传统意义上的“副作用”或“非特异性结合”，而是一种可以被主动设计、精确控制的药物属性。这一观点将长期被视为风险的“promiscuity”，重新定义为治疗复杂疾病的关键优势。 其次，论文创新性地将 AI 技术视为连接“化学空间—靶点空间—生物网络”的统一引擎。与以往仅将机器学习用于单靶点预测不同，本文系统梳理了多任务 QSAR、蛋白-化学联合建模（Proteochemometrics）、生成式深度学习、强化学习以及图神经网络在多靶点场景下的协同作用，构建了一个从数据输入到分子生成、再到实验反馈的闭环逻辑。 第三，论文突

医学研究前沿——聚焦医学前沿研究进展。100多万医学领域硕博医生们订阅的微信公众号。点击标题下蓝字“医学研究前沿”关注，我们将为您提供最有价值、最前沿的医学前沿资讯。 阿尔茨海默病（AD）作为全球老龄化社会面临的重大公共卫生挑战，其发病机制呈现高度复杂性。传统淀粉样蛋白级联假说主导的研究范式面临瓶颈，单靶点干预策略在临床试验中屡遭失败，提示AD本质上是氧化应激、神经炎症与多种调节性细胞死亡（RCD）通路紊乱共同作用的多因素疾病。在此背景下，核因子红系2相关因子2（Nrf2）/血红素加氧酶-1（HO-1）信号轴因其独特的抗氧化应激调控特性，逐渐成为学界关注的焦点。 内蒙古医科大学第五临床医学院联合多单位开展的这项系统性综述，通过整合700余篇文献的循证证据，首次构建了Nrf2/HO-1通路与AD病理进程的深度关联网络。研究团队创新性地建立"细胞死亡模式-氧化应激-Nrf2/HO-1调控"三维分析框架，详细阐明了铁死亡（脂质过氧化驱动）、焦亡（炎性小体活化）、凋亡（线粒体损伤）及自噬-内质网应激失衡等四种主要RCD类型的分子机制及其交互作用。尤为重要的是，该研究首次系统揭示了Nrf2/HO

点击蓝字 关注我们 每年2月4日 是国际抗癌联盟（UICC）确立的 “世界癌症日” 2026年，全球抗癌事业迎来新的共识—— 以人为本，携手抗癌 这一主题强调了抗癌不仅仅是患者个人的事情 而是需要全社会的共同参与 随着医学不断进步，癌症正逐渐从“绝症”转为可防可治的慢性病，越来越多患者得以长期生存。 近年来，厦门各大医院在肿瘤诊治领域不断突破： “核武器”精准剿杀癌细胞、 抗癌“神药”进入厦门、 靶向免疫创新药研发 …… 一系列前沿新技术、新理念落地应用 为患者点亮了希望之光 “核武器”钇90 在肿瘤治疗领域，“核武器”不再是科幻词汇。2023年厦门弘爱医院在闽西南率先运用“核武器”钇90治疗肝癌。近几年，厦门大学附属第一医院、厦门大学附属中山医院、厦门市中医院等也陆续开展钇90治疗。今年初，厦门大学附属第一医院还专门成立了钇90精准肝脏肿瘤介入治疗中心。 钇90原理是什么？ 钇90是一种放射性核素，目前主要用于中晚期无法手术切除的肝癌、结直肠癌肝转移等肝脏恶性肿瘤治疗。治疗时，医生采取介入手术，将数百万颗携带钇90的树脂微球精准注入肿瘤的供血动脉，如“精准制导”般富集于肿瘤，从肿瘤内

This strategic affiliation increases access to world-class, academic-based gastroenterology and hepatology care throughout the region with the addition of a leading independent GI medical group with more than 60 board-certified providers to TGPN. TAMPA, Fla., Feb. 4, 2026 /PRNewswire/ -- Gastro Florida, a leader in the treatment of the full spectrum of digestive diseases and GI clinical research for more than 15 years, has partnered with Tampa General Hospital (TGH) to expand access to comprehen

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced receipt of a CE Certificate (No. 28620235524 issued January 19, 2026) for the Transpose Ultra® (Sterile Kit) and the Processing Unit (Centrifuge) in accordance with Regulation (EU) 2017/745 on medical devices (the Medical Device Regulation, MDR). Intertek Medical Notified Body AB (2862) conducted an extensive review of the submitted Technical Documentation and per

Major Nationwide Coverage Expansion by the Blue Cross Blue Shield Association and Multiple BCBS Independent Licensees (Member Plans) Position the Remote Electrical Neuromodulation Wearable Device as a Widely Reimbursed, Mainstream Migraine Treatment Option BRIDGEWATER, N.J. and NETANYA, Israel, Feb. 4, 2026 /PRNewswire/ -- Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions, today announced that health insurance co